Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
07:00am, Thursday, 08'th Aug 2024
Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold ® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti ® + Opfolda ® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 202
NCLA Amicus Brief in NY Case Against Trump Explains Why NY's Executive Law Violates Free Speech
06:01pm, Friday, 02'nd Aug 2024
People of the State of New York, By State Attorney General Letitia James, against Donald J. Trump, et al. People of the State of New York, By State Attorney General Letitia James, against Donald J. Tr
In NCLA Amicus Win, Fifth Circuit Rules Against FCC's Unlawful Control of Universal Service Fund
06:05pm, Wednesday, 24'th Jul 2024
Washington, D.C., July 24, 2024 (GLOBE NEWSWIRE) -- Today, the en banc U.S. Court of Appeals for the Fifth Circuit ruled in Consumers' Research v.
In NCLA Amicus Win, Supreme Court Upholds Small Business's Right to Judicial Review
12:09pm, Monday, 01'st Jul 2024
Corner Post, Inc. v. Board of Governors of the Federal Reserve System Corner Post, Inc. v. Board of Governors of the Federal Reserve System
In NCLA Amicus Win, Supreme Court Restores Americans' Rights to Trial by Jury
12:01pm, Thursday, 27'th Jun 2024
Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C. Securities and Exchange Commission v. George R. Jarkesy, Jr. and Patriot28, L.L.C.
In NCLA Amicus Win, Fifth Circuit Upholds Permanent Block on Treasury's Illegal State Tax Cut Ban
01:48pm, Wednesday, 26'th Jun 2024
State of Texas; State of Mississippi; State of Louisiana v. Janet Yellen, Richard K. Delmar, U.S. Department of the Treasury, United States of America State of Texas; State of Mississippi; State of Lo
In NCLA Amicus Win, Supreme Court Overturns NLRB-Specific Preliminary Injunction Standard
11:55am, Thursday, 13'th Jun 2024
Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB Starbucks Corporation v. M. Kathleen McKinney, Regional Director of Region 15 of the NLRB
In NCLA Amicus Win, Tenth Circuit Clears Path to Toppling Intrusive Dog Kennel Inspection Regime
11:00am, Tuesday, 11'th Jun 2024
Scott Johnson, Harlene Hoyt, Covey Find Kennel, LLC v. Justin Smith, D.V.M., in his official capacity as Animal Health Commissioner at the Kansas Department of Agriculture Scott Johnson, Harlene Hoyt,
In NCLA Amicus Win, Fifth Circuit Topples SEC's Unlawful Effort to Regulate Private Funds
01:06pm, Wednesday, 05'th Jun 2024
National Association of Private Fund Managers, et al. v. Securities and Exchange Commission National Association of Private Fund Managers, et al. v. Securities and Exchange Commission
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
07:00am, Wednesday, 05'th Jun 2024
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Health
3 Biotech Names Under $10 I Own
10:18am, Sunday, 02'nd Jun 2024
Today, we take a look at three promising biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability, and the other is cash rich and has several partner
Amicus Therapeutics: Too Cheap At Under $10 A Share
05:06am, Monday, 20'th May 2024
Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth. The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seei
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
11:50am, Friday, 10'th May 2024
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
11:30pm, Thursday, 09'th May 2024
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Str
Amicus Therapeutics, Inc. (FOLD) Q1 2024 Earnings Call Transcript
03:14pm, Thursday, 09'th May 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - C
